Jade Biosciences falls on planned equity offering

Jade Biosciences

03/06/2026 22:10

** Jade Biosciences' JBIO.O shares down 6.2% after hours to $16.50 as it looks to raise equity
** Autoimmune diseases-focused biotech announces offering comprised of stock and pre-funded warrants; deal size not disclosed
** Jefferies, TD Cowen and UBS joint bookrunners
** Co intends to use net offering proceeds to fund clinical trials, preclinical studies, R&D, and for capex, among other purposes
** With ~49.4 mln shares outstanding, co has about $870 mln market cap
** JBIO stock ended Weds down 0.9% at $17.59, up 14% YTD
** 6 analysts rate the stock "strong buy", the other 4 "buy"; median PT of $43.50 up from $24.50 a month ago, according to LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))